Fairer Winds For Pharma? Elan Approval Gives“Product Story” New Meaning
Executive Summary
Elan's approval of the multiple sclerosis therapy Tysabri made it the drug stock to beat in 2004, with the biggest gain among companies tracked on the "F-D-C Reports" indices of biotech and pharma stocks.